86 - Say It Don’t Spray It: Examining the Perspectives on Aerosols and Virus Transmission

Friday, October 1, 2021

11:30 AM - 12:45 PM EDT

Moderator(s)

Tom Talbot, III, MD, MPH

Chief Hospital Epidemiologist
Vanderbilt University Medical Center
Nashville, TN, United States

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Speaker(s)

Hilary Babcock, MD, MPH, FSHEA, FIDSA

Professor
Department of Medicine, Division of Infectious Diseases
Washington University in St. Louis
St. Louis, Missouri, United States

I do not have any relevant financial / non-financial relationships with any proprietary interests.
William Bennett, PhD

Professor of Medicine
University of North Carolina at Chapel Hill
Chapel Hill, NC, United States

I do not have any relevant financial / non-financial relationships with any proprietary interests.
David Weber, MD, MPH

Professor of Medicine, Pediatrics and Epidemiology
Medicine and Pediatrics
University of North Carolina School of Medicine
Chapel Hill, NC, United States

Merck (Individual(s) Involved: Self): Consultant; PDI (Individual(s) Involved: Self): Consultant; Pfizer (Individual(s) Involved: Self): Consultant; Sanofi (Individual(s) Involved: Self): Consultant; UVinnovators (Individual(s) Involved: Self): Consultant

Participants should be aware of the following financial/non-financial relationships:

Tom Talbot, III, MD, MPH: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Hilary Babcock, MD, MPH, FIDSA, FSHEA: I do not have any relevant financial / non-financial relationships with any proprietary interests.

William D. Bennett, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.

David J. Weber, MD, MPH: Merck (Individual(s) Involved: Self): Consultant; PDI (Individual(s) Involved: Self): Consultant; Pfizer (Individual(s) Involved: Self): Consultant; Sanofi (Individual(s) Involved: Self): Consultant; UVinnovators (Individual(s) Involved: Self): Consultant

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit

No CPE credits

Learning Objectives:

At the conclusion of this session, participants will be able to:

review evidence surrounding modes of transmission of the SARS-CoV-2 virus
discuss differences in opinion regarding interventions designed to reduce SARS-CoV-2 transmission
explain the necessary scientific questions and projects needed to improve the understanding of SARS-CoV-2 transmission

Presentations:

Putting the Perspectives Together: Next Steps to Prevent Healthcare-associated Viral Infections
Speaker: Hilary Babcock, MD, MPH, FIDSA, FSHEA – Washington University School of Medicine
The Aerosol Scientist Perspective
Speaker: William D. Bennett, PhD – University of North Carolina at Chapel Hill
The Healthcare Epidemiologist's Perspective
Speaker: David J. Weber, MD, MPH – University of North Carolina School of Medicine